Abeona Therapeutics (ABEO) News Today $5.00 -0.12 (-2.34%) Closing price 04:00 PM EasternExtended Trading$5.00 0.00 (0.00%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Abeona Therapeutics' (ABEO) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research note on Monday.March 25 at 8:12 AM | marketbeat.comAbeona Therapeutics (NASDAQ:ABEO) Upgraded at StockNews.comStockNews.com raised shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday.March 25 at 2:05 AM | marketbeat.comEarnings call transcript: Abeona Therapeutics reports Q4 2024 EPS beatMarch 22 at 4:49 PM | uk.investing.comOppenheimer maintains Abeona Therapeutics Outperform ratingMarch 22 at 4:49 PM | uk.investing.comAbeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2024 Earnings Call TranscriptMarch 22 at 4:49 PM | msn.comAlliance Global Partners Sticks to Its Buy Rating for vTv Therapeutics (VTVT)March 22 at 1:45 AM | markets.businessinsider.comAbeona Therapeutics: Positive Outlook Amid FDA HopesMarch 21, 2025 | tipranks.comAbeona Therapeutics (NASDAQ:ABEO) Posts Earnings Results, Beats Estimates By $0.11 EPSAbeona Therapeutics (NASDAQ:ABEO - Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.11.March 21, 2025 | marketbeat.comAbeona Therapeutics Inc.: Abeona Therapeutics Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch PlansMarch 21, 2025 | finanznachrichten.deAbeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparationsMarch 21, 2025 | msn.comQ4 2024 Abeona Therapeutics Inc Earnings CallMarch 21, 2025 | finance.yahoo.comAbeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...March 21, 2025 | gurufocus.comAbeona Therapeutics Reports 2024 Financial ResultsMarch 21, 2025 | tipranks.comQ4 2024 Abeona Therapeutics Inc Earnings Call TranscriptMarch 21, 2025 | gurufocus.comAbeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comAbeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch PlansMarch 20, 2025 | globenewswire.comAbeona Therapeutics (ABEO) Expected to Announce Quarterly Earnings on MondayMarch 15, 2025 | americanbankingnews.comAbeona Therapeutics at Leerink’s Global Healthcare Conference: Launch Plans for PZcellMarch 12, 2025 | investing.comAbeona Therapeutics (ABEO) Projected to Post Earnings on MondayAbeona Therapeutics (NASDAQ:ABEO) will be releasing earnings before the market opens on Monday, March 17, Financial Modeling Prep reports.March 10, 2025 | marketbeat.comAbeona Therapeutics (NASDAQ:ABEO) Coverage Initiated by Analysts at OppenheimerOppenheimer assumed coverage on shares of Abeona Therapeutics in a research note on Wednesday. They issued an "outperform" rating and a $16.00 price objective for the company.March 6, 2025 | marketbeat.comOppenheimer Initiates Coverage of Abeona Therapeutics (ABEO) with Outperform RecommendationMarch 5, 2025 | msn.comAbeona Therapeutics initiated with an Outperform at OppenheimerMarch 5, 2025 | markets.businessinsider.comAbeona Therapeutics® to Present at the Leerink Partners Global Healthcare ConferenceMarch 4, 2025 | globenewswire.comAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 3, 2025 | globenewswire.comStockNews.com Downgrades Abeona Therapeutics (NASDAQ:ABEO) to SellStockNews.com cut shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday.February 22, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Abeona Therapeutics (NASDAQ:ABEO)HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research report on Wednesday.February 20, 2025 | marketbeat.comAbeona Therapeutics Inc (NASDAQ:ABEO) Short Interest UpdateAbeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) was the recipient of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 2,480,000 shares, a drop of 6.8% from the January 15th total of 2,660,000 shares. Currently, 6.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 273,400 shares, the days-to-cover ratio is presently 9.1 days.February 17, 2025 | marketbeat.comAbeona Therapeutics (NASDAQ:ABEO) Stock Rating Upgraded by StockNews.comStockNews.com upgraded Abeona Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday.February 14, 2025 | marketbeat.comabrdn plc Sells 102,639 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO)abrdn plc decreased its position in Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 31.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 224,356 shares of the biopharmaceutical company's stock after selling 102,63February 11, 2025 | marketbeat.comAbeona Therapeutics Inc.'s (NASDAQ:ABEO) Shift From Loss To ProfitFebruary 7, 2025 | finance.yahoo.comStockNews.com Upgrades Abeona Therapeutics (NASDAQ:ABEO) to "Hold"StockNews.com raised shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday.February 4, 2025 | marketbeat.comAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 3, 2025 | globenewswire.comAbeona Therapeutics Inc (NASDAQ:ABEO) Director Sells $21,520.00 in StockFebruary 1, 2025 | insidertrades.comInsider Sell: Mark Alvino Sells 4,000 Shares of Abeona Therapeutics Inc (ABEO)January 31, 2025 | gurufocus.comInsider Selling: Abeona Therapeutics Inc (NASDAQ:ABEO) Director Sells 4,000 Shares of StockAbeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) Director Mark Alvino sold 4,000 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $5.38, for a total transaction of $21,520.00. Following the completion of the sale, the director now directly owns 64,334 shares of the company's stock, valued at approximately $346,116.92. This trade represents a 5.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.January 31, 2025 | marketbeat.comAbeona Therapeutics: Despite Some Competitive Pressure, This Looks UndervaluedJanuary 24, 2025 | seekingalpha.comAbeona Therapeutics Inc (NASDAQ:ABEO) Director Sells $20,400.00 in StockJanuary 22, 2025 | insidertrades.comInsider Sell: Mark Alvino Sells 4,000 Shares of Abeona Therapeutics Inc (ABEO)January 21, 2025 | gurufocus.comMark Alvino Sells 4,000 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) StockAbeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) Director Mark Alvino sold 4,000 shares of the company's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $5.10, for a total transaction of $20,400.00. Following the completion of the sale, the director now owns 68,334 shares in the company, valued at $348,503.40. This represents a 5.53 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.January 21, 2025 | marketbeat.comAbeona Therapeutics (NASDAQ:ABEO) Cut to Sell at StockNews.comStockNews.com lowered Abeona Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday.January 9, 2025 | marketbeat.comAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 31, 2024 | globenewswire.comOwning 43% shares,institutional owners seem interested in Abeona Therapeutics Inc. (NASDAQ:ABEO),December 28, 2024 | uk.finance.yahoo.comAbeona Therapeutics (NASDAQ:ABEO) Rating Lowered to Sell at StockNews.comStockNews.com cut Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday.December 12, 2024 | marketbeat.comAbeona Therapeutics Inc (NASDAQ:ABEO) is Western Standard LLC's 3rd Largest PositionWestern Standard LLC raised its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 7.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,698,097 shares of the biopharmaceutical companyDecember 6, 2024 | marketbeat.comIkarian Capital LLC Reduces Position in Abeona Therapeutics Inc (NASDAQ:ABEO)Ikarian Capital LLC cut its holdings in shares of Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 24.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 583,593 shares of the biopharmaceutical coDecember 3, 2024 | marketbeat.comWalleye Capital LLC Trims Holdings in Abeona Therapeutics Inc (NASDAQ:ABEO)Walleye Capital LLC cut its position in shares of Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 13.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 861,301 shares of the biopDecember 2, 2024 | marketbeat.comAbeona Therapeutics (NASDAQ:ABEO) Upgraded to Hold at StockNews.comStockNews.com upgraded shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday.November 28, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for ABEO FY2024 Earnings?Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Stock analysts at HC Wainwright lifted their FY2024 EPS estimates for Abeona Therapeutics in a report released on Monday, November 25th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings perNovember 27, 2024 | marketbeat.comAbeona Therapeutics Inc (NASDAQ:ABEO) Shares Sold by Propel Bio Management LLCPropel Bio Management LLC reduced its position in Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 50.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 624,022 shares of the biopharmaceutical company's stock after selling 624,022 sharesNovember 26, 2024 | marketbeat.comAbeona Therapeutics (NASDAQ:ABEO) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Abeona Therapeutics in a report on Monday.November 25, 2024 | marketbeat.com Remove Ads Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address ABEO Media Mentions By Week ABEO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABEO News Sentiment▼0.560.68▲Average Medical News Sentiment ABEO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABEO Articles This Week▼202▲ABEO Articles Average Week Remove Ads Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Gyre Therapeutics News Oculis News Cogent Biosciences News Day One Biopharmaceuticals News Evolus News Avadel Pharmaceuticals News Pharvaris News Avid Bioservices News uniQure News AbCellera Biologics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABEO) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
